TY - JOUR
T1 - Current evidence and issues of endoscopic submucosal dissection for gastric neoplasms during antithrombotic therapy
AU - Kono, Yoshiyasu
AU - Hirata, Issei
AU - Katayama, Tetsuya
AU - Uemura, Hisahiro
AU - Hirata, Tetsu
AU - Gotoda, Tatsuhiro
AU - Miyahara, Koji
AU - Moritou, Yuki
AU - Nakagawa, Masahiro
N1 - Publisher Copyright:
© 2020, Japanese Society of Gastroenterology.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Endoscopic submucosal dissection (ESD) for gastric neoplasms is a useful treatment globally. However, postoperative bleeding after gastric ESD is a serious, and sometimes life-threatening complication in patients receiving antithrombotic drugs, because antithrombotic drugs are considered to increase the risk of postoperative bleeding after gastric ESD. In contrast, withdrawal of antithrombotic drugs during the perioperative period increases the risk of thrombotic complications. Guidelines for the management of antithrombotic drugs during the periendoscopic period have been published by different countries, and recent guidelines place greater emphasis on the risk of thromboembolism with the discontinuation of antithrombotic drugs than on the risk of bleeding with the continuation of antithrombotic drugs. Several studies have reported on the validity of these guidelines, and clinical evidence is being established. Most studies reported that gastric ESD under continuation of aspirin or cilostazol did not increase the risk of bleeding, whereas heparin replacement was strongly associated with a higher risk of bleeding. However, the data regarding some clinical issues about the management of antithrombotic drugs, such as the safety of gastric ESD under continuation of thienopyridine, administration of multiple antithrombotic drugs including dual antiplatelet and anticoagulants (warfarin and direct oral anticoagulant), and effective prophylactic methods for postoperative bleeding after gastric ESD are lacking. Larger clinical data are needed to resolve the remaining issues in the future.
AB - Endoscopic submucosal dissection (ESD) for gastric neoplasms is a useful treatment globally. However, postoperative bleeding after gastric ESD is a serious, and sometimes life-threatening complication in patients receiving antithrombotic drugs, because antithrombotic drugs are considered to increase the risk of postoperative bleeding after gastric ESD. In contrast, withdrawal of antithrombotic drugs during the perioperative period increases the risk of thrombotic complications. Guidelines for the management of antithrombotic drugs during the periendoscopic period have been published by different countries, and recent guidelines place greater emphasis on the risk of thromboembolism with the discontinuation of antithrombotic drugs than on the risk of bleeding with the continuation of antithrombotic drugs. Several studies have reported on the validity of these guidelines, and clinical evidence is being established. Most studies reported that gastric ESD under continuation of aspirin or cilostazol did not increase the risk of bleeding, whereas heparin replacement was strongly associated with a higher risk of bleeding. However, the data regarding some clinical issues about the management of antithrombotic drugs, such as the safety of gastric ESD under continuation of thienopyridine, administration of multiple antithrombotic drugs including dual antiplatelet and anticoagulants (warfarin and direct oral anticoagulant), and effective prophylactic methods for postoperative bleeding after gastric ESD are lacking. Larger clinical data are needed to resolve the remaining issues in the future.
KW - Antithrombotic therapy
KW - Delayed bleeding
KW - Endoscopic submucosal dissection
KW - Thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85087720084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087720084&partnerID=8YFLogxK
U2 - 10.1007/s12328-020-01171-y
DO - 10.1007/s12328-020-01171-y
M3 - Review article
C2 - 32643119
AN - SCOPUS:85087720084
VL - 13
SP - 650
EP - 659
JO - Clinical Journal of Gastroenterology
JF - Clinical Journal of Gastroenterology
SN - 1865-7257
IS - 5
ER -